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The purpose of this study was to determine whether striatal positron emission tomography (PET) 
and single-photon emission computed tomography (SPECT) imaging could be used to differentiate 
the atypical parkinsonian disorders multiple-system atrophy (MSA), progressive supranuclear palsy 
(PSP) and corticobasal syndrome (CBS) from the typical Parkinson disease (PD) for clinical and 
differential diagnostic purposes. Presynaptic tracers for dopamine transporter (DAT), aromatic 
amino acid decarboxylase (AADC) and vesicular monoamine type 2 (VMAT2) were investigated. 
 
A metaanalysis of 35 published presynaptic dopaminergic brain imaging studies of parkinsonian 
disorder patients and healthy controls was performed. PubMed was screened for eligible studies, 
and studies that fulfilled inclusion criteria determined by the study group were identified and 
included. Available striatal tracer binding values, disease severity scores as well as data concerning 
imaging methodology were extracted manually from the included studies. Collected data was 
synthesized using Meta-Essentials, with a statistical significance cut-off at 2-tailed P<0.05. Hedges 
g was used to estimate effect size in group comparisons. The data was screened for heterogeneity, 
and quality evaluation was performed using the Ottawa-Newcastle Scale.  
 
Key results from the synthesis showed a statistically significant difference in striatal DAT binding 
between PSP and PD, while PD and MSA-C or CBS did not demonstrate a significant difference. 
Caudal, but not putaminal DAT binding was significantly different between PD and MSA with 
predominant parkinsonism (MSA-P). A further significant DAT binding difference of 31.4% was 
found between the atypical parkinsonian syndromes PSP and MSA with predominant cerebellar 
ataxia (MSA-C). Clinical MSA subtypes MSA-C and MSA-P showed a 40.6% difference in DAT 
binding. The meta-analysis demonstrated a lower presynaptic dopaminergic function in PSP 
compared to both PD and MSA-P as measured by DAT binding, which may be diagnostically 
significant. The study provides evidence for the loss of caudate-to-putamen dopaminergic deficit 
gradient in MSA compared to PD. 
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Multiple-system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome 
(CBS) have signs and symptoms overlapping those of Parkinson disease (PD), complicating their 
clinical diagnosis. Although presynaptic dopaminergic brain imaging with PET and SPECT is 
clinically widely used for patients with suspected PD, the benefit of functional imaging in atypical 
parkinsonism syndromes remains unclear. We compared striatal presynaptic dopaminergic 
function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS, and PD 
using combined quantitative data from all published studies.  
 
Methods: The PubMed database was searched from inception to August 2018 for the terms 
“dopamine” OR “dopaminergic” AND “PET” OR “SPECT” OR “SPET” and keywords related to PD, 
MSA, PSP, and CBS. In total, 1,711 publications were identified. PET or SPECT studies comparing 
patients with atypical parkinsonism to another diagnostic group (PD, MSA, PSP, or CBS) were 
included. Tracers for dopamine transporter (DAT), aromatic amino acid decarboxylase (AADC), or 
vesicular monoamine type 2 were investigated. Tracer binding data were extracted from the 
original articles. Heterogeneity of the data was examined using I2 statistics, and a random-effects 
model was used to summarize data. Hedges g was used as an estimator of effect size in group 
comparisons. Results are reported according to PRISMA guidelines.  
 
Results: Thirty-five studies (29 DAT, 6 AADC, no vesicular mono- amine type 2 studies) with 356 
MSA-P patients, 204 PSP patients, 79 CBS patients, and 62 MSA-C patients were included in the 
metaanalysis. Caudate nucleus and putamen DAT function was clearly lower in PSP than in PD 
(caudate: 34.1% difference, g 5 −1.08, 95% confidence interval [CI] 5 −1.52 to −0.64; putamen: 
18.2%, g 5 −0.86, 95% CI 5 −1.50 to −0.21) and MSA-P (striatum: 31.4%, g 5 −0.70, 95% CI 5 −1.21 
to −0.19) and was clearly lower in MSA-P than in MSA-C (striatum: 46.0%, g 5 1.46, 95% CI 5 0.23 
to 2.68). Although not significant because of limited data, aromatic L-AADC results paralleled the 
DAT findings.  
 
Conclusion: Striatal presynaptic DAT function is clearly lower in PSP patients than in PD and MSA-P 








Multiple-system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome 
(CBS) have been termed atypical parkinsonian disorders and are characterized by a more rapid 
progression and poorer prognosis than the typical parkinsonian disorder, Parkinson disease (PD). 
Clinicopathologic studies have pointed out that the diagnostic accuracy of atypical parkinsonism is 
not optimal; these disorders are underdiagnosed, and many patients who carry a diagnosis of PD 
in fact have MSA, PSP, or CBS.1 The sensitivities of the MSA and PSP diagnoses are low, at 53% and 
64%, respectively, when diagnosed by general neurologists, and at 88% and 84%, respectively, 
when diagnosed by movement disorder specialists.2,3 Given that there are distinct proteinopathic 
disease mechanisms in different atypical parkinsonian syndromes and that there are active 
attempts to develop protein-specific therapies, biomarkers that could be used to improve 
diagnostic accuracy would be valuable. 
 
Functional brain imaging with PET or SPECT enables the investigation of central neurotransmitter 
function at the system level in vivo. When PD patients are compared with healthy individuals via 
striatal dopaminergic PET/SPECT, the PD patients show a widespread presynaptic defect with 
practically no overlap with healthy controls.4 However, it remains unclear whether presynaptic 
dopamine imaging can be used in the differential diagnosis of atypical parkinsonism. Protein-
specific tracers for tau and α-synuclein hold promise as possible future diagnostic tools5, but in the 
current clinical imaging of movement disorders, presynaptic dopaminergic imaging dominates the 
field. A major limitation in individual dopaminergic neuroimaging studies of atypical parkinsonism 
has been the small sample sizes, which have led to insufficient statistical power to make reliable 
clinical inferences. 
 
A quantitative metaanalysis offers an opportunity to investigate a large number of small studies 
with improved power to detect differences. A previous metaanalysis using diagnostic odds ratios 
has suggested that presynaptic dopaminergic tracers cannot distinguish between PD and atypical 
parkinsonism.6 To investigate the role of presynaptic dopaminergic PET and SPECT in the diagnosis 
of atypical parkinsonism in more detail, we performed a metaanalysis of all available imaging data 
using regional binding values in each study. 
 
MATERIALS AND METHODS 
 
Aims of the metaanalysis 
 
The primary aim of the metaanalysis was to investigate differences in striatal dopamine signaling 
as measured by PET/SPECT among atypical parkinsonism disorders as compared with PD. Ethics 
Committee approval was waived because this study did not involve any human participants or 
animals. 
 
Study collection and screening 
 
The Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) statement 
was followed.7 Studies for initial screening were identified through PubMed using a search query 
of key words related to parkinsonism disorders (Fig. 1). The final database search was conducted 
 
on August, 8, 2018. The initial screening and assessment for eligibility were performed by 2 
investigators. 
This study was an extension of a previously reported metaanalytical comparison between PD 
patients and healthy controls, using the same methodology.4 Studies were first screened on the 
basis of relevance in the title and abstract. Full-text articles were obtained and assessed if the 
articles were deemed relevant to the analysis, if their eligibility could not be determined from the 
title and abstract alone, or if the abstract was not available on PubMed. Dopaminergic synaptic 
mechanisms included in the analysis were aromatic L-amino acid decarboxylase (AADC), dopamine 
transporter (DAT), and vesicular monoamine trans- porter type 2 (VMAT2). Other criteria for 
inclusion are shown in Fig. 1. MSA studies that reported separate binding values for MSA 
parkinsonism variant (MSA-P) patients or MSA cerebellar variant (MSA-C) patients or both were 
included. Studies that did not specifically state MSA subgroups were considered to involve MSA-P, 
the more common subtype, if supported by the clinical features (i.e., the patients had 
parkinsonism). Studies that combined the binding values of MSA-P and MSA-C patients were 
 
excluded from the MSA comparisons. In the PSP studies, only Richardson syndrome phenotype 
patients were included. 
Figure 1.  Flowchart of study inclusion and exclusion. CBD = corticobasal degeneration. 
Data extraction 
 
The study site, imaging method, and tracer binding values were extracted from the included 
studies. Variables extracted were the study year; first author name and institution; tracer 
compound and target; method of calculation for binding values; scanner model; sample sizes; 
mean and SD for age, duration of disease, motor and total Unified Parkinson’s Disease Rating Scale 
(UPDRS) scores, and minimum/maximum Hoehn and Yahr scale scores; mean prescan carbidopa 
dose (mg) in the AADC studies; mean or range of dose of injected tracer (MBq); scan duration 
(min); and binding values for each brain region analyzed. Hemispheric values were used to derive 
bilateral mean values if these were not provided in the original publication. If only medians and 
ranges of the variables were reported, the missing mean values and SDs were generated 
statistically as described previously.8 If necessary, the mean values and ranges were calculated 
using the individual patient data from the original articles when possible. For longitudinal studies, 
the time point from which the most data could be gathered was chosen to represent the study. 
When mean binding ratios (BRs) were reported (BR = [region of interest]/reference), they were 
converted to specific binding ratios (SBRs) (SBR = ([region of interest]−reference)/reference) by 
subtracting 1 (SBR = BR - 1). 
 
The most common investigated brain regions were the mean (bilateral) caudate nucleus (25 
studies), mean putamen (21 studies), mean striatum (15 studies), contralateral caudate nucleus 
(11 studies), ipsilateral caudate nucleus (11 studies), mean posterior putamen (9 studies), mean 
anterior putamen (8 studies), contralateral putamen (8 studies), and ipsilateral putamen (8 
studies). Asymmetry indices for the putamen were reported in 6 studies, and putamen-to-caudate 
ratios were reported in 6 studies. For the AADC studies, sufficient data were available only for the 
mean caudate nucleus and mean putamen. 
 
Risk of publication bias and quality of studies 
 
The risk of publication bias was considered and examined using funnel plots of the studies 
included in the synthesis (comparisons with 10 or more samples). The quality of the included 




The study results and group comparisons were synthesized using Meta-Essentials (version 1.1; 
Erasmus Research Institute of Management).10 Statistical significance was set at 2-tailed P value of 
less than 0.05. Hedges g was used as an estimator of effect size in group comparisons using the 
random-effects model. Heterogeneity of the data was examined using I2 statistics. If substantial 
heterogeneity (I2 > 50%) was detected, metaregression analyses of age, disease duration, and 













Twenty-nine DAT studies (Supplemental Table 1) and 6 AADC studies (Supplemental Table 2) were 
included in the metaanalysis.11-38 There were no suitable VMAT2 studies. Four studies39-42 that had 
combined MSA-P patients with MSA-C patients were excluded from the MSA analysis 
(Supplemental Table 3). Only 1 study reported binding values also in PSP parkinsonism variant 
patients43, which were not included in the analysis. The final sample thus included 35 studies that 
described DAT or AADC binding in 958 PD, 356 MSA- P, 204 PSP, 79 CBS, and 62 MSA-C patients. 
The demographic and clinical characteristics of the patients are presented in Table 1. The quality 
evaluation of the included studies is presented in Supplemental Table 4. Twenty-five studies 
received 5–6 stars, and 10 studies received 3–4 stars (out of 6 stars) in the Newcastle– Ottawa 
scale. The overall quality of the studies was therefore sufficient, but the PET/SPECT imaging 
methodology and resolution were suboptimal in studies that had been published in the 1990s. 
There was some variation in diagnostic criteria as well (Supplemental Table 5), although many 
studies used published and commonly applied criteria for PD44, PSP45, and MSA46,47. 
The DAT studies were published between 1998 and 2018. The tracers used were 123I-ß-CIT, 123I-FP-
CIT, 99mTc-TRODAT, 18F-FP- CIT, and 123I-IPT. Most included studies had calculated striatum-specific 
binding ratios using the occipital cortex as the reference region, and the values were expressed as 
([region of interest] − [occipital cortex])/[occipital cortex]) (Supplemental Table 1). The AADC 
studies were published between 1990 and 1997 and used 6-18F-fluoro-ʟ-dopa as the tracer. 
 
Atypical parkinsonism versus PD 
 
The PSP patients had lower DAT binding than did the PD patients in the mean caudate (weighted 
relative difference = 34.1%, Table 2), mean putamen (18.2%, Fig. 2, Table 2), mean striatum (Table 
2), contralateral caudate, ipsilateral caudate, and anterior putamen (Supplemental Table 6). The 
MSA-P patients had lower DAT binding than did the PD patients in the mean caudate (Table 2). 
There were no differences between PD patients and patients with MSA-C or CBS, but the total 
numbers of patients and studies were low (Table 2). There were no differences in AADC activity 
between the PD and PSP or MSA-P patients, although directions of differences were similar to the 
DAT analysis (Supplemental Table 7). There were insufficient data for other AADC comparisons. 
 
Differences between types of atypical parkinsonism 
 
The PSP patients had 31.4% lower mean striatal DAT binding (weighted relative difference) than 
did the MSA-P patients (Fig. 2; Table 2). The MSA-P patients had 46.0% lower DAT binding than did 
the MSA-C patients in the striatum (Fig. 2; Table 2). No other significant differences were 
observed. The primary results with DAT imaging remained the same when only studies that had 
used similar diagnostic criteria (Supplemental Table 5) were included in the analysis. There were 
no suitable studies that had compared PSP with MSA-C patients, nor were there any that had 
compared CBS patients with those who had other types of atypical parkinsonism. There were no 
 
differences in AADC activity between PSP and MSA-P patients, and there were insufficient data for 
other comparisons (Supplemental Table 7). 
 
 
Metaregression analyses and publication bias 
 
There were no significant associations in metaregression analyses using disease duration or the 
mean motor UPDRS values as moderators. The only significant relationship observed was between 
the Hoehn and Yahr scale and the effect size for caudate DAT binding in the PD versus MSA-P 
comparison (Supplemental Table 8), indicating that a higher difference in the Hoehn and Yahr 
scale scores between the PD and MSA-P groups was associated with a greater difference in 
caudate nucleus DAT binding between these groups. Funnel plots of the comparisons that had 
sufficient numbers of studies did not suggest missing studies that would have implied publication 
bias (Egger regressions, P > 0.05). 
 
Table 1. Summary of demographic and clinical details of samples in included studies. Numbers or 
weighted (for number of subjects for each study) mean values and weighted SDs (in parentheses) 
are presented. 
 
Target Variable PD MSA-P PSP CBS MSA-C 
DAT Samples (n) 26 18 16 5 5 
 Patients (n) 877 285 181 77 62 
 Age (y) 64 (9) 63 (9) 67 (7) 68 (8) 62 (8) 
 Sex (M/F ratio) 1.5 1.0 1.3 0.7 1.1 
 Disease duration (y) 4.6 (3.6) 3.2 (1.9) 3.2 (1.9) 3.0 (1.3) 3.2 (1.9) 
 Hoehn and Yahr scale 2.1 (0.7) 3.4 (0.8) 3.2 (0.9) 3.0 (0.8) 3.5 (1.1) 
 Motor UPDRS score 23 (11) 37 (13) 33 (11) 35 (13) 30 (11) 
AADC Samples (n) 6 5 3 1 0 
 Patients (n) 81 71 23 2 0 
 Age (y) 58 (6) 57 (7) 66 (5) 65 (5) - 
 Sex (M/F ratio) 2.1 1.6 3.3 1.0 - 
 Disease duration (y) 8.3 (6.3) 4.7 (3.3) 3.3 (1.8) 4.0 (0) - 
 Hoehn and Yahr scale 2.7 (0.8) 3.3 (0.8) 3.3 (-) - - 















Table 2. Summary of DAT results. CI = 95% confidence interval for g; n = number of studies or 
patients; I2 = heterogeneity index. There were no available studies that have compared MSA-C 
patients with PSP or CBS patients. There were also insufficient data for MSA-P vs. CBS comparison. 
Statistically significant comparisons are indicated with stars. Hemispheric values and ratios are 


















g = 0.73 g = -0.33 g = -0.37 g = 1.20 
Insufficient 
data, n = 1/17 
 
CI = −0.77 
to −0.01* 
 
CI = -1.52 
to −0.64* 
CI = −1.18 to 
2.63 
 
CI = −1.08 
to 0.43 
 
CI = −1.13 
to 0.39 
 













n =2/92, I2 = 
0.0% 
n =3/122, 
I2 = 0.0% 
n =5/114, 
I2 = 47.7% 
n =3/99, 
I2 = 45.6% 
- 
Putamen 
g = −0.27 
 
g = −0.86* g = 1.51 g = 0.55 g = −0.47 g = 1.87* 
Insufficient 
data, n = 1/17 
 
CI = −0.58 
to 0.04 
 
CI = −1.50 
to −0.21* 
CI = −0.57 to 
3.59 
 
CI = −0.42 
to 1.53 
 
CI = −1.22 
to 0.28 
 





n = 9/451, 
I2 = 29.5% 
n = 8/291, 
I2 = 
73.3%* 
n = 2/92, I2 = 
0.0% 
n = 3/122, 
I2 = 26.8% 
n = 4/101, 
I2 = 27.5% 
n = 3/99, 
I2 = 34.1% 
- 
Striatum g = −0.34 g = −1.05 
Insufficient 
data, n = 1/55 
g = 0.98 g = -0.70* g = 1.46* g = 1.30 
 
CI = −1.01 
to 0.33 
CI = −1.68 
to −0.43* 
- 
CI = −0.65 
to 2.62 
 
CI = −1.21 
to −0.19* 
 
CI = 0.23 
to 2.68* 
 




n = 4/255, 
I2 = 46.6% 
n = 9/390, 
I2 = 73.3% 
- 
n = 4/142, 
I2 = 81.3% 
n = 3/83, 




n = 2/29, 




Figure 2. Forest plots of key comparisons in DAT studies. A. Significant putaminal difference 
between PD and PSP. B. Nonsignificant putaminal difference between PD and MSA-P. C. Significant 






The results of this metaanalysis indicated that striatal DAT binding is lower in PSP patients than in 
either MSA-P or PD patients. Another important finding was that caudate DAT binding is lower in 
MSA-P patients than in PD patients, without significant differences in the putamen. The third 
major finding was that striatal DAT binding is clearly lower in MSA-P patients than in MSA-C 
patients. Although not significant because of limited data, AADC results paralleled the findings 
with DAT. The data concerning VMAT2 and CBS are currently insufficient. 
 
Dopaminergic function is lower in PSP than in either MSA-P or PD 
 
Our results show that presynaptic dopaminergic function, as measured by DAT binding, is up to 
34% lower in PSP than in MSA-P or PD. It has been demonstrated that there is a profound loss of 
nigral dopaminergic neurons in PSP48, and on the basis of the present results, this loss may exceed 
that seen in other types of degenerative parkinsonism, at least when patients are examined by 
means of functional brain imaging 3–5 y after symptom onset. Comparative neuropathologic data 
are needed to investigate whether the greater loss of presynaptic dopamine function in PSP is 
present at all disease stages and whether this loss of dopamine function is based on greater 
neuronal loss or a functional difference in the nigrostriatal tract. There are data suggesting that PD 
and PSP patients may have similar losses of A9 dopamine neurons in the substantia nigra49, 
whereas the number of A10 neurons is clearly lower in PSP than in PD50. From a clinical 
perspective, it is important to note that the markedly lower DAT binding in the PSP patients 
compared with the PD or MSA-P patients does not seem to be directly related to clinical 
differences in motor symptom severity. For example, although the motor symptoms of the PSP 
patients were less advanced than those of the MSA-P patients (motor UPDRS score, 33 vs. 37, 
respectively), the striatal dopaminergic degeneration was clearly more progressed (31.4% lower in 
the PSP patients than in the MSA-P patients). 
 
Relative differences in the striatal DAT binding between PSP and MSA-P/PD were large, at 18%–
34% (Hedges g > 0.70). The magnitudes are possibly diagnostically significant. Currently, many 
semiautomatic analysis systems used clinically for DAT SPECT have taken advantage of published 
cohorts of healthy subjects (e.g., Varrone et al.51), and clinical diagnostics is aided by the 
automatic flagging of abnormal striatal values as compared with the reference values. In the 
future, automated analysis could possibly be extended to atypical parkinsonism by including 
reference values for PD, PSP, MSA-P, and MSA-C. However, this would not be an easy task, as the 
pathologic level is not constant across the disease course, and the system would need to contain 
information about not only the age and sex of the patients but also the motor symptom severity 
and disease duration. Achieving this task may not be possible in the immediate future, but an 
endeavor toward this purpose could possibly be performed via the international collection of large 
numbers of scans of patients with atypical parkinsonism.52 
 
Caudate dopaminergic loss differentiates MSA-P from PD 
 
The results also showed that while there does not seem to be a difference in putaminal 
dopaminergic function between MSA-P and PD, there is a difference in the caudate nucleus. 
Indeed, one previously suggested possibility for improving the dopaminergic diagnostic accuracy 
 
of atypical parkinsonism is the use of caudate- to-putamen or putamen-to-caudate ratios, as it has 
been suspected that the rostrocaudal gradient of the dopaminergic deficit is lost in atypical 
parkinsonism.53,54 We were unable to perform metaanalytic calculations of these ratios because 
the measurements were variably reported. Nevertheless, the results indirectly support the notion 
that the caudate-to-putamen ratio may be affected in MSA. This is another issue that merits the 
further large multisite collection of clinical scans for comparison. An automated comparison of the 
caudate-to-putamen ratio to those from a large pool of clinically well-characterized patients with 
PD and atypical parkinsonism could prove valuable. These data would optimally be based on 
measurements from PET scans because of the superior spatial resolution, which allows clearer 
separation of striatal subregions than on SPECT scans.53 In the included studies, the binding values 
for the hemispheres contra- and ipsilateral to the predominant motor symptoms were also only 
sporadically reported. The lack of reported subregional and hemispheric values conveys a message 
to the neuro- imaging community. To successfully perform similar metaanalyses in the future, 
more precise reporting of regional binding values (each contra- and ipsilateral region for each 
group together with SDs) or open data sharing is needed. 
 
MSA-P and MSA-C differ in striatal dopamine function 
 
There was a strikingly large 46.0% difference in striatal DAT binding between the MSA-P and MSA-
C patients (Hedges g = 1.46, 4 studies with 133 patients). DAT imaging therefore appears useful in 
the differentiation of MSA subtypes. However, rather than being dichotomically different 
pathologic entities, MSA-P and MSA-C are likely to represent a neuropathologic continuum with 
mixed neuropathology.55 It is possible that MSA-P and MSA-C patients included in neuroimaging 
trials are particularly well characterized and represent extreme ends of the continuum. Therefore, 
the large difference in striatal DAT binding between the MSA-P and MSA-C patients possibly does 
not fully represent clinical reality, in which patients with mixed phenotypes are more frequent. 
Nevertheless, the magnitude of the difference is noteworthy, and we argue that striatal DAT 
imaging could be one of the auxiliary diagnostic tools for patients with mild parkinsonism, 
dysautonomic features, and variable levels of cerebellar findings. The second consensus diagnostic 
criteria of MSA suggested that in the absence of parkinsonian features in a patient with cerebellar 
ataxia, imaging evidence of a nigrostriatal presynaptic deficit points to the diagnosis of MSA-C.47 
The present results do not directly contradict this interpretation, but the results demonstrate that 
it is not the MSA-C subtype but rather the MSA-P phenotype that shows the robust loss of 





The results presented here were derived almost solely from DAT imaging using various tracers. We 
did not identify suitable VMAT2 studies, and the number of AADC studies was low (6 studies 
published in the 1990s). Therefore, we do not currently know if the diagnostic value of DAT 
imaging in atypical parkinsonism is superior to or worse than other presynaptic imaging targets. 
Although AADC function may be somewhat upregulated in PD and the DAT is possibly 
downregulated56, we do not consider it likely that the differences reported here would be 
markedly different if VMAT2 or AADC were the target. Another limitation is that the level of the 
present evidence precludes definitive conclusions about the dopaminergic function in CBS because 
the numbers of studies and patients were low. It is also debatable whether it is useful to classify 
 
PSP and CBS as different disorders.57,58 It should also be noted that the results of the present 
metaanalysis do not necessarily well represent clinical diagnostic reality, because many of the 
included studies were performed with patients who had already been clinically diagnosed at the 
time of imaging. Finally, medications were variably reported and it was therefore impossible to 




The results of this metaanalysis demonstrate that PSP is associated with the greatest presynaptic 
dopaminergic loss compared with other degenerative parkinsonian syndromes. The observed 
large difference between MSA-P and MSA-C may also be clinically useful in patients with 
dysautonomia. Given the magnitude of the differences between the diagnostic groups, an effort 
could be initiated to collect and analyze clinical scans that could be used to create reference and 
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